InMed Pharmaceuticals Inc. INM
dollar amounts stated herein are in U.S. dollars unless specified otherwise.
are a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands
of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part
of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors
Last close
1.44
2026-10-23
Market cap
$4.8M
2026-03-31 share count
52-week range
0.57 - 2.33
Valuation FY2025 figures against the last close
P/S1.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.36
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $4.6M | $4.1M | $1.1M | $1.9M | — | — |
| Cost of revenue | $3.2M | $3.5M | $2.7M | $545.9K | — | — | — |
| Gross profit | $1.7M | $1.1M | $1.4M | $543.5K | — | — | — |
| R&D | $2.9M | $3.2M | $3.7M | $7.3M | $5.3M | $5.8M | — |
| SG&A | $6.6M | $5.8M | $5.8M | $6.9M | $4.5M | $3.2M | — |
| Total operating expenses | $9.7M | $9.3M | $9.8M | $17.8M | $9.9M | $9.2M | — |
| Operating income | — | — | -$7.9M | -$18.6M | -$10.2M | — | — |
| Interest expense | — | — | — | — | $360.4K | — | — |
| Pre-tax income | -$8.2M | -$7.7M | -$7.9M | -$18.6M | — | — | — |
| Income tax | — | $7.1K | $13.1K | — | — | — | — |
| Net income | -$8.2M | -$7.7M | -$7.9M | -$18.6M | -$10.2M | -$8.9M | — |
| EPS, basic | -8.36 | -20.14 | -3.25 | -33.17 | -37.96 | — | — |
| EPS, diluted | -8.36 | -20.14 | -3.25 | -33.17 | -37.96 | -1.71 | — |
| Shares, diluted (wtd. avg.) | 975,985 | 381,053 | 2.4M | 560,829 | 268,793 | 5.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.1M | $6.6M | $8.9M | $6.2M | $7.4M | $5.8M | $9.8M |
| Short-term investments | $43.4K | $43.1K | $44.4K | $44.8K | $46.5K | $42.4K | — |
| Receivables | $465.1K | $352.8K | $260.4K | $88.0K | $11.9K | $45.3K | — |
| Inventory | $961.2K | $1.2M | $1.6M | $2.5M | — | — | — |
| Total current assets | $12.9M | $8.7M | $11.3M | $9.6M | $8.4M | $6.3M | — |
| Property, plant and equipment | $992.2K | $1.2M | $723.4K | $904.3K | $326.6K | $403.5K | — |
| Other intangibles | $1.6M | $1.8M | $1.9M | $2.1M | $1.1M | $1.1M | — |
| Total assets | $15.6M | $11.8M | $14.1M | $12.8M | $9.8M | $7.8M | — |
| Accounts payable | $1.4M | $1.7M | $1.6M | $2.4M | $2.1M | $1.6M | — |
| Total current liabilities | $1.8M | $2.0M | $2.0M | $3.3M | $2.2M | $1.7M | — |
| Total liabilities | $2.1M | $2.6M | $2.0M | $3.7M | $2.4M | $1.9M | — |
| Retained earnings | -$117.2M | -$109.1M | -$101.4M | -$93.5M | -$74.9M | -$64.6M | — |
| Total equity | $13.4M | $9.2M | $12.1M | $9.1M | $7.4M | $5.9M | $14.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.8M | -$7.0M | -$7.3M | -$15.6M | -$9.8M | -$7.4M | — |
| Depreciation and amortisation | $212.8K | $219.6K | $202.2K | $185.7K | $120.9K | $112.4K | — |
| Stock-based compensation | $119.3K | $137.7K | $278.2K | $697.9K | $610.2K | $994.4K | — |
| Capital expenditure | $0 | $9.3K | $160.0K | $39.1K | $1.7K | $42.6K | — |
| Investing cash flow | $0 | -$9.3K | -$661.8K | -$673.0K | -$1.7K | $3.8M | — |
| Financing cash flow | $12.3M | $4.7M | $10.7M | $15.1M | $10.9M | -$31.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-294455.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1.9M | $1.1M | $4.1M | $4.6M | $4.9M |
| Gross profit | — | — | — | $543.5K | $1.4M | $1.1M | $1.7M |
| Net income | — | -$8.9M | -$10.2M | -$18.6M | -$7.9M | -$7.7M | -$8.2M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Change of control Control of the company has changed hands. Item 5.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |